SCLC Expert Addresses Key FAQs on ADCs, T-Cell Engagers, and First-Line Strategies
Image supplied with the source report: Onclive.

Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.

Source disclosure

This is a source-linked briefing. Read the original report from Onclive .

Science us Onclive